Condition: Malignant Neoplasm · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of HER3-DXd in children and if they tolerate it * What happens to HER3-DXd in children's bodies over time * If children who receive HER3-DXd have the cancer get smaller or go away
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Childrens Hospital Los Angeles ( Site 3006) | Los Angeles, California, United States | Recruiting |
| Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 3016) | Aurora, Colorado, United States | Recruiting |
| Yale New Haven Hospital ( Site 3012) | New Haven, Connecticut, United States | Recruiting |
| Johns Hopkins All Children's Hospital ( Site 3025) | St. Petersburg, Florida, United States | Recruiting |
| University of Iowa Health Care Holden Comprehensive Cancer Center ( Site 3017) | Iowa City, Iowa, United States | Recruiting |
| Dana-Farber Cancer Institute ( Site 3013) | Boston, Massachusetts, United States | Recruiting |
| Corewell Health ( Site 3001) | Grand Rapids, Michigan, United States | Recruiting |
| Children's Mercy Hospital ( Site 3024) | Kansas City, Missouri, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 3008) | New Brunswick, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 3010) | New York, New York, United States | Recruiting |
| New York Medical College ( Site 3023) | Valhalla, New York, United States | Recruiting |
| Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 3003) | Fargo, North Dakota, United States | Recruiting |
+ 51 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06941272